A twice-yearly injection may soon change how high blood pressure is treated. In a global trial, patients receiving the experimental drug zilebesiran alongside standard therapy saw greater blood pressure reductions than those on standard treatment alone. The drug works by blocking a key liver protein, helping blood vessels relax. Researchers say this long-lasting approach could make it much easier for patients to keep their condition under control.
View the full article